Protocol for A Systematic Review and Meta-Analysis of Studies on the Use of Brain Natriuretic Peptide and N-Terminal Brain Natriuretic Peptide Levels in the Diagnosis of Cardiopulmonary Edema in Acute Respiratory Failure

Takero Terayama (✉ takero.for.medical.journal@gmail.com)
National Defense Medical College Hospital  https://orcid.org/0000-0002-3002-5343

Takuya Taniguchi
Department of Cardiovascular Medicine, Otsu City Hospital, Shiga, Japan

Ryosuke Imai
Department of Pulmonary Medicine, Thoracic Center, St. Luke’s International Hospital, Tokyo, Japan

Keisuke Anan
Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

Takuo Yoshida
Intensive Care Unit, Department of Anesthesiology, Jikei University School of Medicine, Nishi-Shinbashi Minato-ku, Tokyo, Japan

Koichi Ando
Division of Allergology and Respiratory Medicine, Department of Medicine, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo, Japan

Satoshi Okamori
Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan

Yohei Okada
Department of Primary Care and Emergency Medicine, Graduate School of Medicine, Kyoto University, Preventive Services, School of Public Health, Kyoto, Japan

Protocol

Keywords: Respiratory failure, acute respiratory distress syndrome, cardiopulmonary edema, brain natriuretic peptide, meta-analysis, diagnostic accuracy test

DOI: https://doi.org/10.21203/rs.3.rs-52602/v1
Abstract

Background

Dyspnea with bilateral pulmonary edema is common among patients in emergency departments (EDs) or intensive care units (ICUs). For the initial management of patients with this condition, cardiopulmonary edema (CPE) must be differentiated from acute respiratory distress syndrome (ARDS) in clinical settings. Brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) are useful in distinguishing these conditions. However, current data about the use of these indexes are limited. Hence, we planned to perform a systematic review and meta-analysis to determine the accuracy of the two indexes for the diagnosis of CPE.

Methods

We designed and registered a study protocol for a systematic review and meta-analysis. This study aims to determine the diagnostic accuracy of BNP and NT-proBNP based on the standards of the methodology of the Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy and the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies in reporting the findings of this review. We will search PubMed (MEDLINE), Cochrane Library, www.clinicaltrials.gov, and International Clinical Trials Registry Platform. Randomized controlled trials and observational cohort studies reporting the accuracy in diagnosing CPE among adult patients with dyspnea and bilateral pulmonary edema will be included in the analysis. Two reviewers will independently screen articles, extract data, and evaluate for quality and bias using the Quality Assessment of Diagnostic Accuracy Studies. Then, a meta-analysis will be performed, and different statistical methods will be used to investigate heterogeneity among studies. A subgroup analysis of elderly patients with left ventricular dysfunction or chronic renal dysfunction will be performed. In the meta-analysis, a hierarchical summary receiver operating characteristic model or a bivariate model will be used in each index test, as appropriate.

Discussion

A systematic review and meta-analysis of the accuracy of BNP and NT-proBNP for the diagnosis of CPE will be conducted. The result of this study can help clinicians to identify an appropriate initial treatment for patients with acute respiratory failure, including those with ARDS and CPE. To the best of our knowledge, this will be the first comprehensive systematic review focusing on ARDS management in a specific population.

Systematic review registration

UMIN-CTR ID: UMIN000040983.
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the acute onset of bilateral alveolar opacities and hypoxemia diagnosed based on the Berlin Definition[1]. Generally, it has a high mortality and morbidity. Moreover, it affects approximately 200,000 individuals and results in 74,500 deaths annually in the United States[2]. Thus, several intensive managements, such as tracheal intubation, mechanical ventilation, and extracorporeal oxygenation, are required. ARDS is believed to be a secondary insult to the lungs, and it is associated with other primary conditions, such as trauma, burn, and infection. Therefore, in addition to the intensive management mentioned above, diagnosis of the primary condition and appropriate treatment are essential to save the lives of individuals with this condition. However, the diagnosis can be challenging in the early stage of illness[3], particularly among patients with advanced age, multiple comorbidities, and polypharmacy[4, 5].

The Berlin Definition is based on a specified acute time frame (within 7 days from onset or deterioration), presence of bilateral opacities on chest radiography or computed tomography (CT) scan, cause of pulmonary edema that cannot be explained by heart failure or volume overload alone, and hypoxia (PaO$_2$/fraction of inspired oxygen [FiO$_2$] [P/F] ratio < 300) [1]. The criteria do not include pulmonary artery wedge pressure (PAWP), which is measured using a right atrial catheter, because it is invasive and costly and has low accuracy in clinical estimation[6]. Then, alternative clinical tools for differential diagnosis, such as biomarker levels, alveolar protein concentration, and echocardiogram results, have been explored[3, 7-10]. Some studies reported that brain natriuretic peptide (BNP) and N-terminal brain natriuretic peptide (NT-proBNP) were useful and highly accurate in distinguishing cardiopulmonary edema (CPE) from acute lung injury (ALI)/ARDS[11, 12]. Komiya conducted a systematic review on systemic biomarkers (BNP, NT-proBNP, C-reactive protein, plasma soluble suppression of tumorigenicity-2, heparin-binding protein, and copeptin levels), lung biomarkers (fluid-to-plasma protein ratio and surfactant apoprotein-A concentration in the bronchoalveolar lavage fluid), and imaging studies (chest ultrasonography, chest CT scan)[13]. This study showed that BNP and NT-proBNP were the most commonly used systemic biomarkers. Moreover, BNP and NT-proBNP are extremely simple to use as they are available in any clinical settings. However, other methods may not be available particularly in low-resource settings.

Current data on whether BNP and NT-proBNP are beneficial for differential diagnosis are limited. Martindale and colleagues conducted a systematic review and meta-analysis on the diagnosis of acute heart failure using BNP and NT-proBNP among patients with dyspnea in an emergency department (ED) setting. They pooled patient-level BNP data from six studies and NT-proBNP data from five studies. Results showed that the areas under the receiver operating characteristic (ROC) curve were 0.86 (95% confidence interval [CI] = 0.83–0.86) for BNP and 0.76 (95% CI = 0.74–0.78) for NT-proBNP[14]. However, there is still no systematic review and meta-analysis that distinguished ARDS from CPE in ED and intensive care unit (ICU) settings. Hence, we planned to conduct a systematic review and meta-analysis on the diagnostic accuracy of both plasma BNP and NT-proBNP among adult patients with acute respiratory failure in ED and ICU settings based on rigorous methodological guidelines[15, 16].
Methods/design

This is a protocol for a systematic review and meta-analysis on the diagnostic test accuracy (DTA) of BNP and NT-proBNP for the detection of CPE in patients with acute respiratory failure. We will adhere to the standards of the methodology of the Cochrane Handbook for Systematic Reviews of DTA[17] and the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Diagnostic Test Accuracy Studies [16] in reporting the findings of this review.

Objectives

This is a protocol for a systematic review and meta-analysis on the diagnostic test accuracy (DTA) of BNP and NT-proBNP for the detection of CPE in patients with acute respiratory failure. We will adhere to the standards of the methodology of the Cochrane Handbook for Systematic Reviews of DTA[17] and the Preferred Reporting Items for Systematic Reviews and Meta-analyses of Diagnostic Test Accuracy Studies [16] in reporting the findings of this review.

Objectives

Primary objective

To determine the accuracy of BNP and NT-proBNP for the diagnosis of CPE in patients with acute respiratory failure.

Secondary objective

To explore the possible sources of heterogeneity, including risk of bias and presence of past medical history, such as renal deficiency and left ventricular dysfunction, among studies assessing BNP and NT-proBNP.

Criteria for studies included in this review

Types of studies

We will include all reports on the accuracy of plasma BNP or NT-proBNP for the diagnosis of CPE among adult patients with acute respiratory failure. Moreover, the study will comprise prospective or retrospective observational (cohort or cross-sectional) studies or secondary analysis of randomized controlled trials. However, diagnostic case-control studies and case studies without sufficient diagnostic test accuracy data, namely true-positive (TP), false-positive (FP), true-negative (TN), and false-negative (FN) values, based on the reference standard will be excluded.

Participants

The target participants are as follows:
• Adult patients aged 15 years or older.
• Patients with acute respiratory failure, dyspnea, and hypoxia who were admitted in the ED or ICU.
• Patients with bilateral pulmonary edema on imaging studies, such as radiography and CT scan.

Index test

The index tests are plasma BNP and NT-proBNP assays using any types of method. We will report these index tests as positive or negative based on the study threshold cutoffs. Studies evaluating both BNP and NT-proBNP in a similar study population will also be included.

BNP and NT-proBNP are different indexes widely used to diagnose heart failure[18, 19]. Currently, an alternative test for cardiac biomarkers is not available. To distinguish ARDS from CPE in patients with acute respiratory failure and bilateral pulmonary edema, the BNP and NT-proBNP tests can be used in addition to echocardiogram, chest radiography, and physical examination.

BNP is synthesized as a prohormone (proBNP), which is then cleaved into the active fragment BNP (32-amino-acid, C-terminal fragment) and the inert fragment NT-proBNP (inactive 76 amino-acid, N-terminal fragment). They are synthesized and released into the circulation by cardiac ventricular myocytes in response to volume expansion and possible increased wall stress. Both are cleared mainly by the kidneys. However, NT-proBNP has a longer half-life (mean: 120 vs. 20 min), and it is more stable than BNP in vitro[20, 21]. The serum BNP and NT-proBNP levels may vary due to kits used in the examination or under some conditions, such as renal dysfunction, obesity, drug-related disorder, inflammation, and cancer[22-25].

Reference standard

The reference standard for the final diagnosis made by experts, such as cardiologists and emergency physicians, refers to all available patients’ information, including clinical features and response to treatment.

The difference between CPE and ARDS in ED and ICU settings commonly comprise the combined results for physical examination, echocardiogram, and invasive evaluation (e.g., PAWP). In echocardiogram, ejection fraction (EF), left ventricular end-diastolic dimension, and diameter of the inferior vena cava are often evaluated. However, the inter-observer agreement for the diagnosis can be low unless these examinations are performed by expert sonographers, including cardiologists. Moreover, in recent years, PAWP has been found to provide inaccurate clinical estimation [26], and there is no clear evidence showing its benefits[27, 28]. The trend was identified based on the Berlin Definition, in which low PAWP (<18 mmHg) is no longer required for the assessment of ARDS[1].

Target conditions

The target condition is CPE, which should have causes different from those of acute respiratory failure during the initial treatment. Acute respiratory failure with bilateral lung infiltrates on chest radiography or
CT scan is common in the ED and ICU settings. In this review, CPE was defined as bilateral lung infiltrates on radiography or CT scan based on the reference standard (18). The timing of the diagnosis ranges from the early stage to the late stage of illness, such as during hospital discharge.

**Clinical settings**

The clinical settings will be in the ED and ICU.

**Search methods used to identify studies**

**Electronic searches**

An electronic search strategy has been developed in collaboration with librarians. To identify all prospective, retrospective, or randomized controlled trials, we will search MEDLINE (via PubMed; from 1966 to the present) and Cochrane Central Register of Controlled Trials in the Cochrane Library. We will search for ongoing and unpublished studies at www.clinicaltrials.gov and the International Clinical Trials Platform (www.who.int/ctrp/en). There are no limits regarding language and publication date for this review. We have outlined the search strategy in Appendix 1. Moreover, the reference lists of relevant articles will be hand searched.

**Data collection and analysis**

**Selection of studies**

Two or more authors will independently screen all articles identified using our search strategy based on the inclusion criteria of this review. Screening will be a two-step process (initial title/abstract screening and full-text screening). Disagreements among reviewers will be resolved via a consensus or third-party reviewer. After the full-text screening, a list of excluded studies with reasons will be provided in the appendix of the final report.

**Data extraction and management**

Two or more authors will develop the data extraction sheet with the following information:

- Study characteristics: author, year of publication, country where the study was conducted, design, sample size, clinical settings, and funding source.
- Population characteristics: inclusion/exclusion criteria, number of dropouts with reason, and demographic characteristics of the participants (such as age and sex).
- Index test: timing of sampling, method of examination, time to result, and name of the person who conducted the test.
- Reference standard: method of examination, time to result, and name of the person who performed the examination.
• Information regarding quality assessment items based on the Quality Assessment of Diagnostics-Accuracy Studies 2 (QUADAS-2) assessment system[15].

• Outcomes: Based on the information in the 2 × 2 table, we will assess diagnostic accuracy parameters, such as TP, FP, TN, and FN values.

Assessment of methodological quality

Two or more investigators will independently evaluate and report the risk of bias using the QUADAS-2 tool[29]. We will assess four domains for the risk of bias, which are as follows: patient selection, index test, reference test, and flow and timing. Moreover, applicability concerning the first three domains will be evaluated. For each domain, we will respond to the questions with a Yes/No/Unclear answer, and the risk of bias will be considered as Low/High/Unclear.

A statistical assessment of publication bias will not be performed. There is no evidence of publication bias in the systematic reviews of diagnostic accuracy, and the methods used in assessing publication bias are not reliable when applied to diagnostic accuracy studies.

The sources of bias in diagnostic accuracy studies include those related to the patients (spectrum bias and selection bias), index test (information bias), reference test (misclassification bias, partial verification bias, differential verification bias, incorporation bias, disease progression bias, and information bias), and data analysis (excluded data bias).

Statistical analysis and data synthesis

We will individually analyze BNP and NT-proBNP. In the included studies, the reference standard (final diagnosis made by experts) will have dichotomous outcomes, and the index tests will have thresholds at which the diagnostic accuracy parameters will be calculated. For all studies, we will establish 2 × 2 tables (multiple tables for a study with multiple thresholds) with data on TP, FP, FN, and TN values in each study. The diagnostic odd ratio will be also calculated, which is a measure of the discriminative power of a test that has been considered a good indicator of test performance[30, 31]. We will use forest plots with 95% confidence intervals (CIs) to assess the sensitivity and specificity in each study. To visually assess the correlation between both indices, the summary of the ROC curve will be plotted when the studies have different cutoffs or the results were presented as circles in the ROC space when the studies had a similar cutoff for reporting sensitivity versus 1-specificity. We expect that the included studies will use different threshold cutoffs for the assessment of sensitivity and specificity because no consensus has been established as to the optimal threshold cutoff of BNP or NT-proBNP for the diagnosis of CPE. In the meta-analysis, we will use a hierarchical summary receiver operating characteristic model to pool data and to estimate and summarize the receiver operating characteristic curve when the studies use different cutoffs. A bivariate model will also be used when the studies use similar cutoffs.

All analyses will be performed using the STATA, SAS (SAS Institute Inc., Cary, NC, the USA), or Review Manager 5 software (Cochrane Collaboration, London, the United Kingdom).
Assessment of heterogeneity

Heterogeneity was assessed using the $I^2$ statistical method, with $I^2 > 50\%$ or $p$-value < 0.05 indicating significant heterogeneity. We want to perform subgroup analyses if the following data are available: age (elderly/adult) and past medical history (left ventricular dysfunction or chronic renal insufficiency).

Sensitivity analyses

We will assess for robustness by excluding studies with a high risk of bias.

Assessment of reporting bias

We will not assess publication or reporting bias as there are no accepted method that can be used for its evaluation in a meta-analysis of diagnostic test accuracy studies[32].

Discussion

This systematic review and meta-analysis aims to provide a summary of existing knowledge on the accuracy of cardiac biomarkers for the diagnosis of CPE among patients with acute respiratory failure. To the best of our knowledge, this protocol will be the first in this field.

Any modifications made to our protocol during the review will be reported in the final paper. We plan to submit the review in a peer-reviewed journal with articles often read by physicians working in the ICU. Further, we believe that this review will also be interesting to non-experts in ARDS.

This protocol can help physicians in selecting an appropriate initial management for patients with acute respiratory failure and bilateral pulmonary edema.

Abbreviations

ARDS: acute respiratory distress syndrome

CT: computed tomography

FiO$_2$: fraction of inspired oxygen

P/F ratio: PaO$_2$/fraction of inspired oxygen ratio

PAWP: pulmonary artery wedge pressure

BNP: brain natriuretic peptide

NT-proBNP: N-terminal brain natriuretic peptide

CPE: cardiopulmonary edema
ALI: acute lung injury
ED: emergency department
ROC: receiver operating characteristic
ICU: intensive care unit
DTA: diagnostic test accuracy
TP: true-positive
FP: false-positive
TN: true-negative
FN: false-negative
EF: ejection fraction
QUADAS-2: Quality Assessment of Diagnostic Accuracy Studies 2
CI: confidence interval

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and materials
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. Materials during the current study are available from the corresponding author upon reasonable request.

Competing interests
The authors declare that they have no competing interests.

Funding
The authors did not receive any funding for this study.
Authors’ contribution

Authors’ contributions
TT was a major contributor in writing the manuscript. TY, KA, SO, and YO conceived and designed the scoping review. All authors contributed to the development of search strategy, the selection criteria, the bias assessment strategy and data extraction criteria. All authors also read, provided feedback and approved the final manuscript.

Acknowledgements

The authors would like to thank Enago (https://www.enago.jp/) for the English language editing service.

References

1. Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS: Acute respiratory distress syndrome: the Berlin Definition. Jama 2012, 307(23):2526-2533.
2. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, Stern EJ, Hudson LD: Incidence and outcomes of acute lung injury. The New England journal of medicine 2005, 353(16):1685-1693.
3. Ware LB, Matthay MA: Clinical practice. Acute pulmonary edema. The New England journal of medicine 2005, 353(26):2788-2796.
4. Lien CT, Gillespie ND, Struthers AD, McMurdo ME: Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas. European journal of heart failure 2002, 4(1):91-98.
5. Hawkins NM, Petrie MC, Jhund PS, Chalmers GW, Dunn FG, McMurray JJ: Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. European journal of heart failure 2009, 11(2):130-139.
6. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O’Connor CM, Sopko G, Califf RM: Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. Jama 2005, 294(13):1664-1670.
7. Fein A, Grossman RF, Jones JG, Overland E, Pitts L, Murray JF, Staub NC: The value of edema fluid protein measurement in patients with pulmonary edema. Am J Med 1979, 67(1):32-38.
8. Milne EN, Pistolesi M, Miniati M, Giuntini C: The radiologic distinction of cardiogenic and noncardiogenic edema. AJR Am J Roentgenol 1985, 144(5):879-894.
9. Aberle DR, Wiener-Kronish JP, Webb WR, Matthay MA: Hydrostatic versus increased permeability pulmonary edema: diagnosis based on radiographic criteria in critically ill patients. Radiology 1988, 168(1):73-79.
10. Nagueh SF, Kopelen HA, Zoghbi WA: Feasibility and accuracy of Doppler echocardiographic estimation of pulmonary artery occlusive pressure in the intensive care unit. Am J Cardiol 1995, 75(17):1256-1262.
11. Komiya K, Ishii H, Teramoto S, Takahashi O, Eshima N, Yamaguchi O, Ebi N, Murakami J, Yamamoto H, Kadota J: **Diagnostic utility of C-reactive protein combined with brain natriuretic peptide in acute pulmonary edema: a cross sectional study.** Respir Res 2011, **12**(1):83.

12. Levitt JE, Vinayak AG, Gehlbach BK, Pohlman A, Van Cleve W, Hall JB, Kress JP: **Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study.** Critical care (London, England) 2008, **12**(1):R3.

13. Komiya K, Akaba T, Kozaki Y, Kadota JI, Rubin BK: **A systematic review of diagnostic methods to differentiate acute lung injury/acute respiratory distress syndrome from cardiogenic pulmonary edema.** Critical care (London, England) 2017, **21**(1):228.

14. Martindale JL, Wakai A, Collins SP, Levy PD, Diercks D, Hiested BC, Fermann GJ, deSouza I, Sinert R: **Diagnosing Acute Heart Failure in the Emergency Department: A Systematic Review and Meta-analysis.** Acad Emerg Med 2016, **23**(3):223-242.

15. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeang MM, Sterne JA, Bossuyt PM: **QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies.** Ann Intern Med 2011, **155**(8):529-536.

16. Mclnnes MDF, Moher D, Thombs BD, McGrath TA, Bossuyt PM, Clifford T, Cohen JF, Deeks JJ, Gatsonis C, Hooft L **et al.: Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA Statement.** Jama 2018, **319**(4):388-396.

17. **Handbook for DTA Reviews | Cochrane Methods Screening and Diagnostic Tests.**

18. Clerico A, Fontana M, Zyw L, Passino C, Emdin M: **Comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and the N-terminal part of the propeptide of BNP immunoassays in chronic and acute heart failure: a systematic review.** Clinical chemistry 2007, **53**(5):813-822.

19. Kantor PF, Lougheed J, Dancea A, McGillion M, Barbosa N, Chan C, Dillenburg R, Atallah J, Buchholz H, Chant-Gambacort C **et al.: Presentation, diagnosis, and medical management of heart failure in children: Canadian Cardiovascular Society guidelines.** The Canadian journal of cardiology 2013, **29**(12):1535-1552.

20. Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C: **Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man.** The Journal of clinical endocrinology and metabolism 1993, **76**(1):91-96.

21. Vanderheyden M, Bartunek J, Goethals M: **Brain and other natriuretic peptides: molecular aspects.** European journal of heart failure 2004, **6**(3):261-268.

22. Mueller C, Laule-Kilian K, Scholer A, Nusbaumer C, Zeller T, Staub D, Perruchoud AP: **B-type natriuretic peptide for acute dyspnea in patients with kidney disease: insights from a randomized comparison.** Kidney international 2005, **67**(1):278-284.

23. Horwich TB, Hamilton MA, Fonarow GC: **B-type natriuretic peptide levels in obese patients with advanced heart failure.** Journal of the American College of Cardiology 2006, **47**(1):85-90.

24. Bando S, Soeki T, Matsuura T, Tobiume T, Ise T, Kusunose K, Yamaguchi K, Yagi S, Fukuda D, Iwase T **et al.: Plasma brain natriuretic peptide levels are elevated in patients with cancer.** PloS one 2017,
25. Talha S, Charloux A, Enache I, Piquard F, Geny B: Mechanisms involved in increased plasma brain natriuretic peptide after heart transplantation. *Cardiovascular research* 2011, **89**(2):273-281.

26. Eisenberg PR, Jaffe AS, Schuster DP: Clinical evaluation compared to pulmonary artery catheterization in the hemodynamic assessment of critically ill patients. *Critical care medicine* 1984, **12**(7):549-553.

27. Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K: Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. *Lancet (London, England)* 2005, **366**(9484):472-477.

28. Sandham JD, Hull RD, Brant RF, Knox L, Pineo GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H *et al.* A randomized, controlled trial of the use of pulmonary-artery catheters in high-risk surgical patients. *The New England journal of medicine* 2003, **348**(1):5-14.

29. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. In: *Ann Intern Med. Volume 155*, edn. United States; 2011: 529-536.

30. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM: The diagnostic odds ratio: a single indicator of test performance. *Journal of clinical epidemiology* 2003, **56**(11):1129-1135.

31. Devillé WL, Buntinx F, Bouter LM, Montori VM, de Vet HC, van der Windt DA, Bezemer PD: Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC medical research methodology* 2002, **2**:9.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- 5.PRISMAPchecklist.docx
- 4.Appendix.docx